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Abstract
Background:   Manipulation of total homocysteine concentration with oral methionine is
associated with impairment of endothelial-dependent vasodilation. This may be caused by increased
oxidative stress. Vitamin C is an aqueous phase antioxidant vitamin and free radical scavenger. We
hypothesised that if the impairment of endothelial function related to experimental
hyperhomocysteinaemia was free radically mediated then co-administration of vitamin C should
prevent this.
Methods:   Ten healthy adults took part in this crossover study. Endothelial function was
determined by measuring forearm blood flow (FBF) in response to intra-arterial infusion of
acetylcholine (endothelial-dependent) and sodium nitroprusside (endothelial-independent).
Subjects received methionine (100 mg/Kg) plus placebo tablets, methionine plus vitamin C (2 g
orally) or placebo drink plus placebo tablets. Study drugs were administered at 9 am on each study
date, a minimum of two weeks passed between each study. Homocysteine (tHcy) concentration
was determined at baseline and after 4 hours. Endothelial function was determined at 4 hours.
Responses to the vasoactive substances are expressed as the area under the curve of change in FBF
from baseline. Data are mean plus 95% Confidence Intervals.
Results:  Following oral methionine tHcy concentration increased significantly versus placebo. At
this time endothelial-dependent responses were significantly reduced compared to placebo (31.2
units [22.1-40.3] vs. 46.4 units [42.0-50.8], p < 0.05 vs. Placebo). Endothelial-independent responses
were unchanged. Co-administration of vitamin C did not alter the increase in homocysteine or
prevent the impairment of endothelial-dependent responses (31.4 [19.5-43.3] vs. 46.4 units [42.0-
50.8], p < 0.05 vs. Placebo)
Conclusions:  This study demonstrates that methionine increased tHcy with impairment of the
endothelial-dependent vasomotor responses. Administration of vitamin C did not prevent this
impairment and our results do not support the hypothesis that the endothelial impairment is
mediated by adverse oxidative stress.
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Background
Homocystinuria was first described in Belfast in 1962 [1],
Carson et al. identified the presence of the amino acid,
homocysteine, in the urine of subjects with marked skel-
etal abnormalities and mental retardation. It was 1969
before McCully made the association between homo-
cysteine and vascular disease [2]. In a postmortem study
of subjects with homocystinuria, and marked increase in
homocysteine concentrations, he noted extensive
atherosclerosis. Untreated these individuals have a high
mortality before the age of 30 years, mostly from vascu-
lar and thrombotic complications [3]. More recently
mild to moderate elevation of total plasma homocysteine
concentration (tHcy) has become recognised as carrying
an increased risk for the development of atherosclerotic
vascular disease [4, 5]. The cause/effect relationship has
not been fully established though, and we await the re-
sults of secondary prevention trials - investigating the ef-
fect of lowering tHcy.
Increasing evidence suggests that homocysteine pro-
motes vascular disease through endothelial damage. In
vitro, homocysteine damaged cultured endothelial cells
in a dose dependent fashion [6]. In primates, dietary ma-
nipulation of tHcy resulted in endothelial damage [7]
and impaired endothelial function [8]. In humans mod-
erate elevation of tHcy was associated with impaired en-
dothelial-dependent vasodilation before overt evidence
of vascular disease [9]. In addition, experimental hyper-
homocysteinaemia induced by oral methionine pro-
duced impaired endothelial-dependent vasodilation in
healthy volunteers [10]. Endothelial-dysfunction is rec-
ognised as an early [11] and potentially reversible marker
[12] of the atherosclerotic process. Endothelial function
can be assessed by measuring changes in forearm blood
flow (FBF) using venous occlusion plethysmography in
response to local infusion of vasoactive substances.
These effects on the endothelium of increased tHcy may
be due to free radical damage [13]. In vitro, exposing cul-
tured endothelial cells to homocysteine results in cell
damage secondary to hydrogen peroxide formation. [6]
Previous studies have demonstrated a beneficial effect
on endothelial function following oral vitamin C, an
aqueous anti-oxidant vitamin, administration in disease
states [14,15,16]. We hypothesised that if the endothelial
damage in experimental hyperhomocysteinaemia were
related to increased oxidative stress, then co-administra-
tion of vitamin C, an anti-oxidant vitamin, should pre-
vent this effect.
Methods
Subjects
Ten healthy male non-smoking volunteers of mean age
23 years (range 21-25) were recruited for this study. The
subjects were recruited from staff and students within
our department. Each underwent a medical history, ex-
amination, ECG and routine laboratory tests. All were
non-smokers with no significant past medical history of
note, not on any current medications or vitamin supple-
ments. This study was approved by the ethics committee
of The Queen's University, Belfast. All subjects gave writ-
ten informed consent for all procedures.
Design
Each subject was studied on three separate occasions. In
a randomised fashion the subjects received oral methio-
nine (100 mg/Kg) in fruit juice plus placebo tablets (Me-
thionine group), methionine in fruit juice plus vitamin C
tablets (Vitamin C group) and methionine-free fruit juice
plus placebo tablets (Placebo group). The study em-
ployed a randomised, single (operator)-blind crossover
design with a minimum of two weeks between studies.
The subjects fasted overnight and abstained from alco-
hol- and caffeine-containing products for 12 hours prior
to the study. Randomisation took place at 9 am on each
study day. Due to the distinctive taste of methionine a
department technician in a room separate from the vas-
cular laboratory performed randomisation and subjects
were informed not to comment on the taste of the drink.
Venous blood samples for tHcy measurement were taken
and placed in ice at baseline (t = 0) and 4 hours (t = 4).
FBF was assessed at 4 hours after randomisation. The
brachial artery was cannulated 30 minutes prior to the
first recording to allow the area to normalise.
Forearm blood flow measurements
Studies took place in a temperature-controlled room
(24-26°C). A 27-gauge needle was inserted under local
anaesthetic into the non-dominant brachial artery to al-
low local intra-arterial drug infusion. With the subject
supine and the arms resting on a support slightly above
the level of the heart FBF was measured by strain gauge
venous occlusion plethysmography. A mercury in silastic
strain gauge was coupled to an electronically calibrated
plethysmograph (Medasonics model SPG16, Newark,
California, USA). The voltage output was transferred to a
Macintosh personal computer (Performa 630, Apple
Computer Inc., Newark, California, USA) with a MacLab
analog-to-digital converter and CHART software (v.
3.4.3) (AD Instruments, Hastings, UK). The mean of 5
consecutive FBF measurements was taken for statistical
evaluation. FBF was expressed as ml/100 ml forearm
volume/min.
Following a period of at least 30 minutes rest, during
which 0.9% saline was infused, basal FBF was measured.
Sodium nitroprusside was infused intra-arterially in 4
incremental doses (3, 6, 9 and 12 nmolmin-1), each for 3BMC Cardiovascular Disorders (2001) 1:1 http://www.biomedcentral.com/1471-2261/1/1
minutes, to assess endothelium-independent vasodilata-
tion with FBF measured in the last minute of each infu-
sion. After a washout period of at least 20 minutes basal
FBF was again measured. Acetylcholine was then infused
intra-arterially into the experimental forearm in 4 incre-
mental doses (60, 120, 180, 240 nmolmin-1), each for 3
minutes, to assess endothelium-dependent vasodilata-
tion with FBF again measured in the last minute of each
infusion. All infusions were administered at a rate of 1
ml/min using a constant rate infusor. The doses used
have previously been shown to have no systemic effect on
heart rate, blood pressure or FBF [17]. FBF was meas-
ured in both arms using the non-cannulated arm as a
control to demonstrate that local vasoactive drug admin-
istration did not have a systemic action.
Plasma homocysteine
Plasma was separated by centrifugation at 950 ×  g for 10
min at 4°C, within 20 min of venepuncture, and stored at
-70°C until analysis. Plasma tHcy was measured accord-
ing to the method of Ubbink et al. [18] using HPLC with
fluorescence detection. At plasma homocysteine concen-
tration of 7.87 µmol/L the inter-assay coefficient of vari-
ation (CV) was 6.8% with an intra-assay CV of 2.6%.
Statistical analysis
The changes in tHcy were compared using a paired sam-
ple t-test.
Basal forearm blood flow between study days was com-
pared by use of a paired sample t-test. The responses to
the vasoactive substances are expressed as the measure
of area under the curve (AUC) of change in forearm
blood flow from baseline, expressed in arbitrary units.
This avoids making multiple comparisons [19]. Results
were analysed using a paired sample t-test.
Data are expressed as mean plus 95% Confidence Inter-
vals. Differences were considered significant at a value of
p < 0.05.
Results
Following oral methionine the tHcy concentration at 4
hours increased significantly (7.5 [6.0-9.0] µmol/L vs.
22.8 [19.8-25.8] µmol/L, p < 0.0001 vs. baseline and
Placebo, Table 1). Co-administration of vitamin C did not
significantly alter the rise in tHcy (7.6 [6.2-9.0] µmol/L
vs. 21.6 [18.3-24.9] µmol/L, p < 0.0001 vs. Baseline and
Placebo, Table 1). There was no change in basal tHcy be-
tween study dates suggesting no carry over effect.
Basal FBF was similar in each group suggesting low in-
tra-experimental variation (Table 1), and basal FBF was
unchanged prior to each drug infusion (data not shown).
FBF in the control arm did not change in response to in-
fusion of any study drug thus confirming that the drug
effects were confined to the experimental forearm (data
not shown).
Table 1: Total homocysteine concentrations, basal forearm blood flow (FBF) plus area under curve (AUC) for change in FBF following 
Placebo, oral Methionine and oral Methionine plus Vitamin C.
Placebo Methionine Methionine +
Vitamin C
Total
Homocysteine Baseline 7.8 [6.1-9.5] 7.5 [6.0-9.0] 7.6 [6.2-9.0]
(µmol/L)
T = 4 hours 7.6 [6.3-8.9] 22.8 [19.8-25.8]* 21.6 [18.3-24.9]*
Basal FBF (ml 100 ml-1 min-1) 2.9 [1.9-3.8] 2.8 [1.5-4.0] 3.0 [1.9-4.1]
AUC endothelial-dependent 46.4 [41.3-51.4] 31.2 [20.5-41.9] † 31.4 [17.6-45.2] †
change in FBF (arbitrary units)
AUC endothelial-independent 22.0 [16.7-27.1] 22.2 [13.1-31.3.] 21.6 [18.3-24.9]
change in FBF (arbitrary units)
Mean difference in AUC from -15.2 [-25.8 - -4.5] -15 [-30-0]
placebo (endothelial-dependent)
Mean difference in AUC
Methionine vs. Vitamin C 0.2 [-18.5-18.9]
(endothelial-dependent)
Data are Mean plus [95% Confidence Intervals] p < 0.0001 vs. baseline & placebo, † p < 0.05 vs. placeboBMC Cardiovascular Disorders (2001) 1:1 http://www.biomedcentral.com/1471-2261/1/1
Following oral methionine the AUC of change in en-
dothelial-dependent FBF from baseline was significantly
reduced compared to placebo, (31.2 arbitrary units [22.1-
40.3] vs.46.4 arbitrary units [42.0-50.8] vs. p < 0.05 vs.
Placebo, Figures 1 & 2, Table 1). Co-administration of vi-
tamin C did not alter this reduction compared to placebo
(31.4 [19.5-43.3] arbitrary units vs. 46.4 [42.0-50.8] ar-
bitrary units, p < 0.05 vs. Placebo, Figures 1 & 2, Table 1).
The mean difference in AUC between the methionine
and vitamin C groups emphasises the lack of difference
these groups (0.2 [-15.9-16.3]) arbitrary units, Table 1).
The endothelial-independent responses were similar in
the placebo (22.0 [16.7-27.3] arbitrary units), methio-
nine (22.2 [13.1-31.3] 22.2 [13.1-31.3] arbitrary units)
and vitamin C groups (21.6 [18.7-24.5] arbitrary units),
and there was no significant difference between groups
(Figure 1).
Discussion
The main findings of this study were that oral methio-
nine (100 mg/Kg) increased tHcy concentration signifi-
cantly at t = 4 hours. This increase was associated with
reduced endothelial-dependent FBF compared to the
placebo group. However, co-administration of vitamin C
(2 g orally), an aqueous phase anti-oxidant, did not alter
the increase in tHcy nor prevent the impairment of en-
dothelial-dependent FBF responses.
Mild to moderated elevation in tHcy is associated with an
increased risk for the development of vascular disease [4,
5, 20], yet whether homocysteine is causal remains to be
completely proven. There are also several negative stud-
ies with regard to homocysteine and vascular disease.
The Atherosclerosis Risk in Communities (ARIC) study
[21] was a prospective trial that and showed that there
was no overall association between tHcy and coronary
artery disease. Also, the Multiple Risk Factor Interven-
tion Trial (MRFIT) [22] failed to demonstrate any asso-
ciation between tHcy and the development of myocardial
infarction. Overall though the balance of evidence sup-
ports the theory that increased tHcy is associated with
increased vascular risk. In a recent meta-analysis
Danesh and Lewington [23] demonstrated that there was
an overall association between elevated tHcy and coro-
nary heart disease. This association was greatest for the
retrospective studies with odds ratio of 1.9 (1.6 - 2.3, 95%
CI), while the association from prospective trials was 1.3
(1.1 - 1.5) and for the retrospective population controlled
studies 1.6 (1.4 - 1.7). We await the results of the second-
ary prevention trials that will look at the effect of lower-
ing tHcy (mostly folic acid based regimes) on vascular
risk; these trials are currently ongoing and will help clar-
ify the issue.
Figure 1
Change in endothelial-dependent and -independent forearm
blood flow responses measured 4 hours after placebo,
methionine and methionine plus vitamin C. Data are mean
plus SEM.
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Figure 2
Area under the curve for change in endothelial-dependent
forearm blood flow responses plus the mean of the differ-
ences, measured 4 hours after placebo, methionine and
methionine plus vitamin C. Data are mean plus 95% Confi-
dence Intervals.BMC Cardiovascular Disorders (2001) 1:1 http://www.biomedcentral.com/1471-2261/1/1
Increasingly evidence suggests that homocysteine exerts
its vascular effect by promoting endothelial damage.
Moderate elevation in tHcy was associated with impaired
endothelial-dependent vasodilation in adults without
overt evidence of vascular disease [9] and dietary manip-
ulation of tHcy in primates induced impairment of en-
dothelial function. [8] This is important, as impairment
of endothelial function is an early and reversible marker
of the atherogenic process [11, 12].
To investigate the possible mechanisms involved in this
process attention has focused on the effects of experi-
mental hyperhomocysteinaemia. Chambers et al. [10]
then Bellamy et al. [24] demonstrated acute impairment
of endothelial-dependent dilation following methionine-
induced (100 mg/Kg) hyperhomocysteinaemia in
healthy volunteers. We have confirmed these findings
though using a different technique to assess endothelial
function. [25] We also demonstrated that the changes
were most likely due to the increase in tHcy, and not me-
thionine. We have also previously shown that a much
lower concentration of methionine (250 mg orally), had
no effect on tHcy or endothelial-dependent vasodilation.
Also in an open study of eight volunteers we demonstrat-
ed that methionine (100 mg/Kg) for 7 days was associat-
ed with increased tHcy but there was no impairment of
endothelial-dependent vasodilation [26].
There are different ways to assess endothelial function.
Briefly, flow mediated dilatation [10, 24] measures the
change in brachial artery diameter, using an ultrasound
probe. Following a period of arterial occlusion, the in-
creased flow (shear forces) stimulates endothelial-de-
pendent vasodilation. This method assesses conduit
vessel responses. Our method [17, 25] measures the
change in forearm blood flow using venous occlusion
plethysmography following the local, intra-arterial infu-
sion of vasoactive substances. This method assesses re-
sistance vessel function.
There is some evidence to suggest that homocysteine
damages the endothelium by increased oxidative stress.
We hypothesised that if the adverse effect on endotheli-
al-dependent function was due to increased oxidative
stress then co-administration with vitamin C should pre-
vent this effect. Vitamin C, or ascorbic acid, is the main
water-soluble anti-oxidant in human plasma and is an
effective scavenger of reactive oxygen species. Previous
studies have demonstrated that vitamin C reversed en-
dothelial vasomotor impairment in-patients with coro-
nary artery disease, [14] chronic cigarette smoking [16]
and hypercholesterolaemia [15].
Chambers and colleagues [27] have reported that admin-
istration of vitamin C (1 g/day for 7 days) prevented the
impairment of conduit vessel endothelial-dependent di-
lation associated with experimental hyperhomocystein-
aemia. Kanani et al. [28] investigated the effect of
methionine-induced hyperhomocysteinaemia on con-
duit and resistance vessel endothelial function. In a sim-
ilar number of subjects and similar protocol to our study,
both authors demonstrated that vitamin C prevented the
impairment of endothelial-dependent vasodilation. Our
data are at conflict with the published material. We could
not demonstrate that vitamin C attenuated the effects of
experimental hyperhomocysteinaemia on endothelial
function when studying resistance vessels, and our data
do not support the theory that the changes are due to in-
creased oxidative stress.
There are several possible reasons for our negative re-
sults, as with any negative study involving small number
of subjects, the possibility of a Type II error is raised. We
feel that as the FBF results in the methionine and vita-
min C group are so similar and the mean difference be-
tween the groups is zero, the possibility of a Type II error
is unlikely. In addition we used similar design and sam-
ple size to the published data. Another possibility is that
the vitamin C levels were not sufficient to produce an ef-
fect. Again this is unlikely as this dose has been previous-
ly validated, we chose 2 g of ascorbic acid orally,
administered at the same time as the methionine; this
dose is known to increase plasma ascorbate concentra-
tions 2.5-fold, with stable concentrations from 2 to 5
hours after dosing. [14] Another possibility is that publi-
cation bias has resulted in under-representation of neg-
ative results.
On closer inspection of the published data there are sev-
eral inconsistencies. The data from Chambers et al. [27]
revealed that administration of vitamin C did not com-
pletely prevent the impairment of endothelial-depend-
ent dilation following oral methionine. In the placebo
group endothelial-dependent stimulation resulted in
brachial artery dilation (4.3 ± 1.0%), following methio-
nine this dilatation was significantly impaired (-0.7 ±
0.8%), while in the methionine plus vitamin C group the
artery dilated 2.8 ± 0.7%. So in this group there was some
dilation, and vitamin C only slightly attenuated the im-
pairment. Their data clearly showed an outlying re-
sponse that had a major influence on the mean value, in
favour of the vitamin C treatment. Therefore we are un-
clear if the authors have in fact demonstrated a signifi-
cant effect. In the paper by Kanani et al. [28] the authors
demonstrated an effect in a similar number to our study.
They demonstrated clearly that administration of vita-
min C completely prevented the impairment of endothe-
lial-dependent vasodilation as assessed by flow-
mediated dilatation (conduit vessel) and venous occlu-
sion plethysmography following intra-arterial infusionBMC Cardiovascular Disorders (2001) 1:1 http://www.biomedcentral.com/1471-2261/1/1
(resistance vessel). It is unclear from the paper how the
authors were able to accurately measure brachial artery
diameter responses when there was a cannula in the ar-
tery.
Recent work questions whether increased oxidative
stress does play a role in homocysteine induced vascular
disease [29]. If oxidative stress due to hyperhomocystei-
naemia plays a role in vascular damage then one might
reasonably expect to detect markers of oxidant stress in
the sera from subjects with homocystinuria, and mark-
edly increased tHcy. This has not been the case however.
LDL isolated from subjects with homocystinuria, and
marked elevation of tHcy, was not more susceptible to
oxidation than control LDL [30]. Markers of lipid perox-
idation were no higher in the serum of subjects than con-
trols [31, 32]. A more recent study, however, using a
more sensitive marker of oxidative damage did suggest a
correlation between tHcy and increased lipid peroxida-
tion (as assessed by F2 isoprostane concentration) [33].
In conclusion, we have been unable to confirm that vita-
min C affects endothelial function in experimental hy-
perhomocysteinaemia. Our results therefore do not
support the hypothesis that methionine induced impair-
ment of endothelial-dependent vasodilation was mediat-
ed by increased oxidant stress.
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